Is This MedTech Giant a Buy for Dividend Investors?
Buying industry-leading companies in industries with growth potential tends to produce delightful results for dividend investors. This is because such businesses can generate revenue and earnings growth, which can fuel rising dividend payments.
The medtech juggernaut (NYSE: SYK) has been a tremendous dividend grower over the years. But is the stock still a buy for investors searching for dividend growth? Let's scrutinize Stryker's fundamentals and current valuation to decide.
Sporting a $106 billion market capitalization, Stryker is the third-biggest medical devices company in the world. This is only behind the respective $188 billion and $113 billion market values of Abbott Laboratories and Medtronic.
Source Fool.com
Stryker Corp. Stock
€326.00
-0.030%
The stock is an absolute favorite of our community with 31 Buy predictions and no Sell predictions.
As a result the target price of 340 € shows a slightly positive potential of 4.29% compared to the current price of 326.0 € for Stryker Corp..
